We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Can Tailored Patient Letters Improve The Quality Of Diabetic Patient Care?

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00984841
First Posted: September 25, 2009
Last Update Posted: September 25, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Scranton-Temple Residency Program
  Purpose
The purpose of this study is to determine if tailored letters sent to diabetic patients will improve care of diabetes.

Condition Intervention
Diabetes Mellitus Other: Tailored letter

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Can Tailored Patient Letters Improve The Quality Of Diabetic Patient Care?"

Further study details as provided by Scranton-Temple Residency Program:

Primary Outcome Measures:
  • Diabetes summary quality measure [ Time Frame: 4 months ]

Enrollment: 467
Study Start Date: January 2009
Study Completion Date: July 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tailored letter
Patients in the tailored letter group received by mail a tailored letter detailing their diabetes measures, together with enclosed orders for lab tests when due, and reminder of or scheduling for an office appointment.
Other: Tailored letter
Active Comparator: Usual Care
Patients in the usual care group were part of a practice wide quality improvement process.
Other: Tailored letter

Detailed Description:

Diabetes care in the US is less than optimal. Some authors have found that targeted patient letters are also an effective tool to improve outcomes when they are part of a comprehensive disease management plan. Local patient satisfaction surveys had revealed that many patients had sub‐optimal understanding of diabetes measures and of the importance of controlling these measures to reduce diabetic complications. We wondered if tailored patient letters and enclosed lab orders when due might increase patient awareness of diabetes measures and increase patient engagement.We hypothesized that the addition of targeted patient letters with enclosed lab orders to an ongoing performance improvement program would further improve diabetes care.

We conducted a randomized controlled study of tailored patient letters and diabetes lab orders at our two resident‐based clinics.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All active patients age 18 to 75 years with a diagnosis of diabetes mellitus were eligible.
  • An active patient was defined as one having an ICD‐9 code on the active problem list identifying the patient as diabetic, and a progress note in the EMR associated with an office visit within the prior 12 months.

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00984841


Locations
United States, Pennsylvania
Scranton-Temple Health Center
Scranton, Pennsylvania, United States, 18510
Sponsors and Collaborators
Scranton-Temple Residency Program
Investigators
Principal Investigator: John R Guzek, MD Scranton-Temple Residency Program
  More Information

Responsible Party: John R Guzek, MD, Scranton-Temple Residency Program
ClinicalTrials.gov Identifier: NCT00984841     History of Changes
Other Study ID Numbers: STRP001
First Submitted: September 24, 2009
First Posted: September 25, 2009
Last Update Posted: September 25, 2009
Last Verified: September 2009

Keywords provided by Scranton-Temple Residency Program:
Diabetes Mellitus targeted mailing

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases